WilmerHale Represents PTC Therapeutics in $1.5B Evrysdi® Royalty Agreement with Royalty Pharma

WilmerHale Represents PTC Therapeutics in $1.5B Evrysdi® Royalty Agreement with Royalty Pharma

Client News

Related Solutions

We guide clients through today’s ever-changing debt markets, representing them in a broad variety of debt deals that range from complex financial structures to traditional loan transactions.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
We leverage technical knowledge, business acumen and legal experience to structure, prepare and negotiate innovative and effective technology-related agreements.
On October 19, 2023, PTC Therapeutics, Inc. (NASDAQ: PTCT) announced an agreement with Royalty Pharma plc. to monetize PTC’s remaining interests in its Evrysdi royalty stream for up to $1.5 billion. Under the agreement, Royalty Pharma acquired certain royalties on Evrysdi for $1.0 billion upfront. The agreement also includes options for PTC to sell up to all of its retained royalties on Evrysdi for up to an additional $500 million, and for Royalty Pharma to acquire half of such retained royalties for up to $250 million at a later date. PTC maintains all economics associated with up to $250 million in remaining commercial sales milestones associated with Evrysdi global net sales.

The agreement builds on the previous strategic partnership established in 2020 with Royalty Pharma.

The WilmerHale legal team advising PTC Therapeutics was led by George Shuster and Nathan Moore with assistance from Emily Powers.
 

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel